SPRO [NASD]
Spero Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.24 Insider Own1.60% Shs Outstand32.61M Perf Week-11.98%
Market Cap24.31M Forward P/E- EPS next Y-1.84 Insider Trans315.89% Shs Float27.63M Perf Month-22.67%
Income-103.20M PEG- EPS next Q-0.55 Inst Own61.30% Short Float5.13% Perf Quarter-90.49%
Sales13.00M P/S1.87 EPS this Y17.50% Inst Trans1.60% Short Ratio1.87 Perf Half Y-94.61%
Book/sh1.92 P/B0.43 EPS next Y27.30% ROA-71.00% Target Price10.50 Perf Year-94.95%
Cash/sh4.15 P/C0.20 EPS next 5Y36.90% ROE-116.90% 52W Range0.73 - 19.87 Perf YTD-94.83%
Dividend- P/FCF- EPS past 5Y-6.20% ROI-64.40% 52W High-95.84% Beta2.03
Dividend %- Quick Ratio1.90 Sales past 5Y122.50% Gross Margin- 52W Low13.02% ATR0.11
Employees146 Current Ratio1.90 Sales Q/Q-71.20% Oper. Margin- RSI (14)29.93 Volatility11.43% 11.19%
OptionableYes Debt/Eq0.00 EPS Q/Q-52.50% Profit Margin- Rel Volume0.29 Prev Close0.74
ShortableYes LT Debt/Eq0.00 EarningsMay 16 AMC Payout- Avg Volume757.14K Price0.83
Recom2.30 SMA20-16.58% SMA50-58.52% SMA200-91.96% Volume218,153 Change11.66%
Oct-01-21Downgrade Oppenheimer Outperform → Perform
Jan-22-21Reiterated H.C. Wainwright Buy $33 → $40
Dec-16-20Initiated Berenberg Buy $47
Sep-29-20Initiated Evercore ISI Outperform
Nov-05-19Reiterated H.C. Wainwright Buy $28 → $35
Sep-09-19Initiated Janney Buy
Feb-09-18Initiated Cantor Fitzgerald Overweight $27
Nov-27-17Initiated Stifel Buy $26
Nov-27-17Initiated Oppenheimer Outperform $30
Nov-27-17Initiated BofA/Merrill Neutral $16
Jun-27-22 04:27PM  
04:05PM  
May-31-22 07:30AM  
May-16-22 05:35PM  
04:05PM  
May-11-22 08:05AM  
May-09-22 08:05AM  
May-04-22 09:15AM  
May-03-22 05:29PM  
12:41PM  
09:59AM  
08:23AM  
07:05AM  
Apr-28-22 03:02PM  
Apr-21-22 08:05AM  
Apr-06-22 05:31PM  
Mar-31-22 05:55PM  
04:05PM  
Mar-29-22 10:39AM  
Mar-28-22 06:51PM  
Mar-17-22 08:05AM  
Feb-16-22 08:05AM  
Feb-10-22 10:47AM  
Jan-20-22 05:36AM  
Jan-19-22 08:05AM  
Jan-04-22 11:38AM  
08:48AM  
08:05AM  
Jan-03-22 08:05AM  
05:03AM  
Dec-28-21 02:38AM  
Nov-17-21 08:05AM  
Nov-12-21 11:06AM  
Nov-10-21 05:45PM  
04:05PM  
Nov-03-21 08:05AM  
Oct-28-21 03:05PM  
08:05AM  
Oct-12-21 08:05AM  
Oct-05-21 07:11AM  
Oct-01-21 04:01PM  
Sep-30-21 03:00PM  
08:00AM  
Sep-28-21 12:45PM  
Sep-16-21 08:05AM  
Sep-07-21 08:05AM  
Sep-02-21 08:46AM  
Aug-31-21 04:25PM  
12:00PM  
Aug-11-21 02:07AM  
Aug-10-21 06:47AM  
Aug-05-21 05:55PM  
04:01PM  
Jul-30-21 04:33PM  
Jul-29-21 04:01PM  
03:05PM  
Jul-07-21 04:01PM  
12:56PM  
Jul-06-21 01:00PM  
Jul-05-21 06:04AM  
Jul-02-21 04:01PM  
Jul-01-21 01:12PM  
Jun-30-21 06:46PM  
Jun-15-21 04:01PM  
Jun-11-21 07:48AM  
Jun-07-21 01:41PM  
May-28-21 05:35PM  
May-17-21 04:01PM  
May-13-21 08:00AM  
May-06-21 06:05PM  
04:01PM  
02:30PM  
Apr-30-21 04:26PM  
Apr-29-21 04:01PM  
Mar-31-21 04:31PM  
Mar-11-21 05:45PM  
04:07PM  
02:30PM  
Mar-09-21 05:31AM  
Mar-08-21 12:30PM  
Mar-03-21 08:30AM  
Feb-25-21 08:30AM  
Feb-05-21 08:00AM  
Jan-29-21 05:17PM  
Jan-26-21 07:00AM  
Jan-21-21 08:00AM  
Jan-08-21 06:21AM  
Dec-17-20 08:00AM  
Dec-16-20 08:30AM  
Dec-11-20 09:09PM  
Dec-10-20 08:00AM  
Dec-02-20 08:30AM  
Nov-30-20 05:01PM  
09:09AM  
Nov-09-20 09:25AM  
Nov-07-20 11:31AM  
Nov-05-20 04:05PM  
02:30PM  
Nov-03-20 08:32AM  
Oct-30-20 12:52PM  
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Aquilo Capital Management, LLC10% OwnerApr 26Buy5.2439,727207,9715,321,231Apr 28 04:13 PM
Aquilo Capital Management, LLC10% OwnerMar 30Buy8.7950,000439,4205,281,504Mar 31 03:51 PM
Aquilo Capital Management, LLC10% OwnerMar 14Buy7.6323,708180,7975,231,504Mar 16 04:23 PM
Aquilo Capital Management, LLC10% OwnerFeb 28Buy9.5344,833427,2275,207,796Mar 02 03:52 PM
Aquilo Capital Management, LLC10% OwnerFeb 18Buy9.2414,828137,0395,162,963Feb 23 04:24 PM
Aquilo Capital Management, LLC10% OwnerJan 31Buy11.59125,0001,448,2625,148,135Feb 01 08:26 PM
Aquilo Capital Management, LLC10% OwnerJan 24Buy10.891,59917,4185,023,135Jan 26 05:12 PM
Aquilo Capital Management, LLC10% OwnerJan 18Buy12.4148,488601,9645,021,536Jan 20 01:07 PM
Aquilo Capital Management, LLC10% OwnerJan 10Buy12.938,867114,6094,973,048Jan 12 04:43 PM
Aquilo Capital Management, LLC10% OwnerDec 31Buy15.75125,0001,969,0254,964,181Jan 03 02:46 PM
Aquilo Capital Management, LLC10% OwnerDec 30Buy15.7750,000788,6104,839,181Jan 03 02:46 PM
Aquilo Capital Management, LLC10% OwnerDec 29Buy14.6475,4931,105,2634,789,181Jan 03 02:46 PM
Mahadevia AnkitCEO and PresidentDec 27Option Exercise5.908,00047,200152,036Dec 29 06:26 PM
Mahadevia AnkitCEO and PresidentDec 27Sale14.588,000116,666144,036Dec 29 06:26 PM
Aquilo Capital Management, LLC10% OwnerOct 29Buy17.53150,0002,630,1754,713,688Nov 02 05:47 PM
Aquilo Capital Management, LLC10% OwnerSep 30Buy18.65134,5432,509,1734,563,688Oct 04 11:36 AM
Aquilo Capital Management, LLC10% OwnerSep 14Buy18.492,15639,8724,429,145Sep 15 07:21 PM
Aquilo Capital Management, LLC10% OwnerSep 13Buy18.5644,210820,6754,426,989Sep 15 07:21 PM
Aquilo Capital Management, LLC10% OwnerSep 09Buy18.5024,749457,7924,382,779Sep 10 05:21 PM
Aquilo Capital Management, LLC10% OwnerAug 31Buy18.9348,645920,6604,358,030Sep 01 05:42 PM
Aquilo Capital Management, LLC10% OwnerAug 30Buy17.8744,042786,8594,309,385Sep 01 05:42 PM
Aquilo Capital Management, LLC10% OwnerAug 27Buy16.8813,957235,5314,265,343Aug 27 05:11 PM
Aquilo Capital Management, LLC10% OwnerAug 26Buy16.5522,982380,3224,251,386Aug 27 05:11 PM
Aquilo Capital Management, LLC10% OwnerAug 24Buy16.2840,170653,7954,228,404Aug 24 04:28 PM
Aquilo Capital Management, LLC10% OwnerAug 23Buy16.33137,8352,251,3424,188,234Aug 24 04:28 PM
Aquilo Capital Management, LLC10% OwnerAug 20Buy14.86221,1903,286,9064,050,399Aug 24 04:28 PM